MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Cytokinetics Inc

Abrir

SetorSaúde

39.71 -1.27

Visão Geral

Variação de preço das ações

24h

Atual

Mín

39.01

Máximo

40.45

Indicadores-chave

By Trading Economics

Rendimento

11M

-150M

Vendas

16M

17M

EPS

-1.26

Margem de lucro

-886.276

Funcionários

498

EBITDA

13M

-125M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+116.74% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.3B

4.5B

Abertura anterior

40.98

Fecho anterior

39.71

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Cytokinetics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de jun. de 2024, 15:26 UTC

Aquisições, Fusões, Aquisições de Empresas

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

5 de jun. de 2024, 14:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5 de jun. de 2024, 14:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5 de jun. de 2024, 14:14 UTC

Aquisições, Fusões, Aquisições de Empresas

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5 de jun. de 2024, 14:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5 de jun. de 2024, 14:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5 de jun. de 2024, 14:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Comparação entre Pares

Variação de preço

Cytokinetics Inc Previsão

Preço-alvo

By TipRanks

116.74% parte superior

Previsão para 12 meses

Média 82.36 USD  116.74%

Máximo 120 USD

Mínimo 54 USD

Com base em 18 analistas de Wall Street que oferecem metas de preço de 12 meses para Cytokinetics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

18 ratings

17

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

37.85 / N/ASuporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.